Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lannett gets hammered 2 quarters in a row. Ouch!!!
Everyday is a quiet period for Elite. Lol
This is a tiny company with tiny profitability. It’s in a generic drug industry. This isn’t rocket science why it’s not flashy.
Elite’s stock has been under 10 cents for years. Value has fluctuated very little. 10 cents, 5 cents, 3 cents with all around the same volume. Little $ exchanging hands regardless.
Not weeks in aggregate, but weeks with every session was under 100K
We have had weeks under 100k volume traded.
A contact doesn’t mean anything. Let’s see if a deal happens and then celebrate afterwards. Few of the many partnerships over the years have been fruitful.
In fact, it doesn’t even require anything to swallow since it’s not approved by the FDA.
Or looking to see if they can supply Elite with some applesauce from their cafeteria.
Wow. Along with a story about puppy dogs and unicorns holding hands under the rainbow.
Insiders leave and then don’t have to disclose after a few months. Jerry sold right away, which had to be disclosed. When is last time any insider bought shares on open market? Even for CEO, it’s been years.
Been dead for years after it hit a brick wall.
Big increase on small number…is still a small number.
Just like how Elite was in catbird seat with SequestOx. How did that end?
Almost an hour into the session. The volume traded is off the charts. Demand is stunning. Kudos to IR team for getting strategic plan and future value out to investors.
Stop the bull. A PR is “little is said”? They touted LaPree more than Dexcel partnership and he was just temporary. Perhaps his latest tenure will last longer than Dexcel? We do seem to have quite the revolving door of distribution partnerships.
Isn’t it funny how they PR LaPree coming on board, but not his departure? Investors can read between the lines here.
Dexcel did not make a strategic investment in Elite. They are a distribution partner that shares in the profit splits of Adderall, just like Lannett. Nothing more, nothing less.
Issues between FDA and KVK date at least back to Feb 2020.
Issues with KVK have been going on for over 2 years and has provided no material tailwind to Elite.
So now we’re in the business of a cleansing opioid detergent?
Yes, his intentions were for a reverse split. This company has a severely bloated share count, not the opposite.
No 8-K is the proof.
It’s all opinion until proven.
Like how FDA couldn’t stop SequestOx per the CEO? Drop mic.
I believe Weezuhl previously commented that it does not work on CNS drugs.
They have been partners since 2018 on an arthritis pain reliever, Diclofenac Sodium Tablets. It’s a non-steroid & anti-inflammatory.
He clearly said Loxapine. Script was simply wrong.
Premium is the key word, not multiple.
There was never a puzzle here. Listen to the call, Nasrat clearly says Loxapine, not Fluoxetine. It’s a typo in the script. He says Loxapine twice. There is no slip up. It’s a product that has already launched that brings in a minuscule amount of revenue.
Working capital = Current assets less current liabilities. Does not equal cash.
No, Sungen antibiotic had a small total market less than 100M.
They don’t, that is a misread.
Antibiotic w/ Sungen is only one that I’m aware of, but didn’t sound like they were willing to respond to the FDA in the required time. Hard shell oxy, but that hasn’t moved for years. Not sure any other filings have been publicly disclosed. No other bioequivalency studies have been released to which a filing would be associated.
I believe we only have a 90-day notification that the contract could be terminated by either party. When the ER reaches certain volume from Lannett’s sales distribution they will terminate and leave Elite scrambling to find another partner and rebuild IR & ER volumes. 2-year contract doesn’t mean much unless termination clause has some teeth to it.
When was last time an insider bought shares on open market? Stock is at all time lows this year and no open market purchases.
Based on the opioid line that got sold off for pennies on the R&D dollar?
Yes. It has been mentioned that Elite knows how much it will cost to but the rights from Mikah.
Stated in previous call.
I believe the terms are already set. It’s who already did the negotiating on behalf of Elite? Probably the past CFO, who is no longer with the organization…